Company intelligence / Profile preview

ForwardVue Pharma

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

Developing a novel long-acting ORAI1 blocker that acts both upstream and downstream of VEGF inhibition for durable administration up to 12 months to treat retinal neovascular disease. The compound has been administered to over 900 patients systemically for cancer treatment, potentially allowing more rapid progress to Phase 2 once IND enabling ocular toxicity testing is completed.

Therapeutic areas: Ophthalmology
Modalities: Small molecules (carboxyamidotriazole)Bio-resorbable implant
Industry: Biotech

Drug pipeline

1 asset

carboxyamidotriazole

Pre-clinical

Indications: Diabetic retinopathy, Age-related macular degeneration, Retinal neovascular disease

Beyond the preview

Go deeper on ForwardVue Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ForwardVue Pharma.

Explore the full profile